Fox Run Management L.L.C. Invests $629,000 in CRISPR Therapeutics AG $CRSP

Key Points

• Fox Run Management L.L.C. has acquired a new stake in CRISPR Therapeutics AG, purchasing 18,473 shares valued at approximately $629,000 during the first quarter.
• Insider Naimish Patel reduced his holdings by 39.32% by selling 3,932 shares, while Director Simeon George significantly increased his stake by acquiring nearly 990,000 shares.
• CRISPR Therapeutics reported a loss of ($1.29) EPS for the last quarter, beating estimates, but with a substantial drop in revenue compared to expectations, totaling only $0.89 million.

Fox Run Management L.L.C. acquired a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 18,473 shares of the company's stock, valued at approximately $629,000.

A number of other institutional investors have also recently added to or reduced their stakes in CRSP. ARK Investment Management LLC grew its holdings in CRISPR Therapeutics by 13.3% in the 1st quarter. ARK Investment Management LLC now owns 10,165,400 shares of the company's stock valued at $345,929,000 after buying an additional 1,192,336 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in CRISPR Therapeutics by 39.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock worth $150,029,000 after purchasing an additional 1,074,238 shares during the period. Capital International Investors grew its stake in shares of CRISPR Therapeutics by 10.3% during the fourth quarter. Capital International Investors now owns 8,743,523 shares of the company's stock worth $344,145,000 after purchasing an additional 816,789 shares during the period. Baker BROS. Advisors LP boosted its stake in CRISPR Therapeutics by 55.1% during the 4th quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company's stock worth $51,483,000 after acquiring an additional 464,936 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in CRISPR Therapeutics by 12.0% during the fourth quarter. Bank of America Corp DE now owns 1,211,509 shares of the company's stock worth $47,685,000 after acquiring an additional 129,746 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Stock Performance

Shares of CRSP stock traded up $1.53 on Friday, hitting $54.35. 956,280 shares of the stock traded hands, compared to its average volume of 2,603,361. The firm's 50-day moving average price is $54.49 and its two-hundred day moving average price is $44.78. The stock has a market capitalization of $4.94 billion, a PE ratio of -10.01 and a beta of 1.80. CRISPR Therapeutics AG has a twelve month low of $30.04 and a twelve month high of $71.13.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its earnings results on Monday, August 4th. The company reported ($1.29) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.18. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.The firm had revenue of $0.89 million during the quarter, compared to analysts' expectations of $6.44 million. During the same period in the previous year, the firm posted ($1.49) EPS. CRISPR Therapeutics's revenue for the quarter was up 72.5% on a year-over-year basis. On average, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insider Activity at CRISPR Therapeutics

In other news, insider Naimish Patel sold 3,932 shares of the firm's stock in a transaction dated Thursday, May 29th. The stock was sold at an average price of $35.94, for a total value of $141,316.08. Following the transaction, the insider directly owned 6,068 shares in the company, valued at $218,083.92. This trade represents a 39.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Simeon George bought 989,812 shares of the company's stock in a transaction that occurred on Wednesday, July 16th. The shares were bought at an average price of $52.03 per share, for a total transaction of $51,499,918.36. Following the completion of the acquisition, the director owned 1,730,179 shares in the company, valued at approximately $90,021,213.37. This trade represents a 133.69% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 4.30% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Piper Sandler reaffirmed an "overweight" rating and set a $105.00 target price on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Chardan Capital reiterated a "buy" rating and set a $82.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, August 5th. Bank of America reduced their price target on CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating for the company in a report on Tuesday, July 22nd. Needham & Company LLC reiterated a "buy" rating and issued a $81.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, July 8th. Finally, Barclays lifted their target price on CRISPR Therapeutics from $42.00 to $56.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. Nine analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, CRISPR Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $71.60.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.